Oversold

ZYME

Same as last week
Valuation50/ 100
Cash flow & growth12/ 100
Upside potential34/ 100
Risk potential47/ 100

ZYME's valuation appears fair, weak fundamentals weigh on the score, while forward estimates point to a return to profit and improving margins, though analyst coverage is limited and estimates vary widely.

Valuation

Valuation stays neutral because earnings are difficult to compare across periods. Business trends, outlook and financial risk still contribute to the overall score.

Cash flow & growth

Business trends are weak. Over the past year: revenue -69.8%, operating margin -351.7 percentage points. Free cash flow is -323.3% of revenue. The business score is 11.8/100. Growth, margins and cash generation drive the score. Missing or older data receives less weight.

Favorable scenario

Weaker business results limit upside support. Price history provides the reference because earnings are difficult to compare.

The calculation starts with the stock’s typical weekly price movements, adjusted for business performance and outlook. Unusually large jumps have less influence. The result is 24.2% upside, or about $32.59.

This is a scenario based on our model, not a forecast or probability.

Downside scenario

The 47.2% downside is driven by operating stress: the model assumes earnings fall 29% and the PE falls 25.6%. That gives $4.65 per share at a 3× PE, or about $13.86. Price swings alone suggest 38.4% downside.

This is a scenario based on our model, not a forecast or probability.

ZYME vs Historical averages

MetricCurrentAverageRelative
PE4x3.3x20% higher
PE percentile824967% higher
EPS-$2.02-$1.83$0.19 lower
FCF-$120M-$81.6M-$38.4M
Loading historical comparisons…

ZYME’s earnings are below their historical averages, while its earnings multiple is higher.

ZYME Forward outlook

MetricOutlook
Forward valuation--
Forward earningsTurning positive
Forward revenueStrong growth
Forward profitabilityStrongly expanding
Analyst coverageLimited
Estimate dispersionWide

ZYME’s outlook is generally improving, supported by an expected return to profitability.

ZYME PE Valuation

Loading pe valuation table…

This table applies ZYME's historical price-to-earnings (PE) landmarks to current earnings. The implied prices are valuation scenarios, not price forecasts or targets.

ZYME Earnings Per Share

Loading earnings per share…

This chart tracks ZYME's trailing twelve-month diluted earnings per share, calculated from four consecutive reported quarters to reduce seasonal noise.

ZYME Quarterly Revenue

Loading quarterly revenue…

This chart tracks ZYME's quarterly revenue over time and shows how sales are changing from year to year.

ZYME Free Cash Flow

Loading free cash flow…

This chart tracks ZYME's free cash flow over time, showing whether the business is consistently generating cash after operating costs and capital spending.

ZYME Total Shares

Loading shares over time…

This chart tracks changes in ZYME's diluted share count. A rising count can dilute existing owners, while a falling count often reflects share repurchases.

ZYME Net Leverage

Loading net leverage…

Quarterly Net Leverage uses the last 12 months of EBITDA. A falling multiple generally indicates less debt relative to earnings capacity. Negative values mean net cash; missing data or nonpositive LTM EBITDA are N/A. The table shows each period’s Net Leverage and status.

ZYME PE vs Healthcare Sector

Loading pe vs sector average…

This chart compares ZYME's price-to-earnings (PE) ratio with the Healthcare sector average. A discount or premium can reflect differences in expected growth, profitability, or risk.

ZYME Weekly Price

Loading weekly price…

This chart uses ZYME's weekly closing prices to show the longer-term trend. The lower panes show weekly RSI and Stochastic momentum.

ZYME Weekly Moving Averages

Loading weekly moving averages…

This chart compares ZYME's 8, 20, 50, 100, and 200-week moving averages from 2020 onward. Shorter averages react faster to price changes, while longer averages show the broader trend.

ZYME Yearly ROI

Loading yearly ROI…

Each line starts at 0% using the year’s first dependable weekly close and tracks the return through December, or through the latest available week for the current year.